The Impact of Micro Troponin, Leak on Long-Term Outcomes Following Elective Percutaneous Coronary Intervention

被引:28
作者
Milani, Richard V. [1 ]
Fitzgerald, Robert [1 ]
Milani, Jenna N. [1 ]
Lavie, Carl J. [1 ]
机构
[1] Ochsner Hlth Syst, Dept Cardiovasc Dis, New Orleans, LA 70121 USA
关键词
troponin; PCI; outcomes; CARDIAC TROPONIN; MYOCARDIAL-INFARCTION; RISK STRATIFICATION; RANDOMIZED-TRIAL; CLOPIDOGREL; PRETREATMENT; ELEVATION; DISEASE; MORTALITY; ABCIXIMAB;
D O I
10.1002/ccd.22160
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the clinical impact of microleaks of troponin, which are below the reference standard defining troponin elevation, on cardiovascular outcomes in stable coronary patients undergoing elective percutaneous coronary intervention (PCI). Background: Troponin elevation, either pre- or post-PCI, has been shown to predict poor cardiovascular outcomes. However, troponin measurements that are above the limit of detection but below the 99th percentile limit defining elevation ("microleak") have uncertain clinical significance. Methods: We assessed subsequent myocardial infarction (MI) and death over a mean follow-up of 4.2 years in 2,272 patients undergoing elective PCI, where baseline troponins were normal and follow-up troponins were obtained 12-24 hr post-PCI. Patients were divided into three groups based on post-PCI troponin levels: Group 1 (n = 1,313) nondetectable; group 2 (n = 587) microleak, and group 3 (n = 372) elevated suggesting myocardial necrosis. Results: The combined endpoint of MI and death was similar in groups 2 and 3 (50.3 vs. 51.9%, respectively, P = NS), which was significantly more than group 1 patients (35.6%, P < 0.01) over the follow-up period. Multivariate analysis of patients in groups I and 2 demonstrated that troponin microleak was an independent predictor of MI and death (P = 0.01). Conclusions: Microleak of troponin following elective PCI suggests myocardial injury and predicts an increased risk of subsequent MI and death. Troponins should be routinely assessed following PCI, and preventive therapies are needed to reduce micro and macro troponin elevation in the PCI setting. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:819 / 822
页数:4
相关论文
共 20 条
[1]   Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes [J].
Antman, EM ;
Tanasijevic, MJ ;
Thompson, B ;
Schactman, M ;
McCabe, CH ;
Cannon, CP ;
Fischer, GA ;
Fung, AY ;
Thompson, C ;
Wybenga, D ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) :1342-1349
[2]   Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology American College of Cardiology consensus recommendations [J].
Apple, FS ;
Quist, HE ;
Doyle, PJ ;
Otto, AP ;
Murakami, MM .
CLINICAL CHEMISTRY, 2003, 49 (08) :1331-1336
[3]   Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) [J].
Bonz, AW ;
Lengenfelder, B ;
Strotmann, J ;
Held, S ;
Turschner, O ;
Harre, K ;
Wacker, C ;
Waller, C ;
Kochsiek, N ;
Meesmann, M ;
Neyses, L ;
Schanzenbächer, P ;
Ertl, G ;
Voelker, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (04) :662-668
[4]   Toward standardization of cardiac troponin I measurements part II: Assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays [J].
Christenson, Robert H. ;
Duh, Show Hong ;
Apple, Fred S. ;
Bodor, Geza S. ;
Bunk, David M. ;
Panteghini, Mauro ;
Welch, Michael J. ;
Wu, Alan H. B. ;
Kahn, Stephen E. .
CLINICAL CHEMISTRY, 2006, 52 (09) :1685-1692
[5]   Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention - Results from the evaluation of drug eluting stents and ischemic events registry [J].
Jeremias, Allen ;
Kleiman, Neal S. ;
Nassif, Deborah ;
Hsieh, Wen-Hua ;
Pencina, Michael ;
Maresh, Kelly ;
Parikh, Manish ;
Cutlip, Donald E. ;
Waksman, Ron ;
Goldberg, Steven ;
Berger, Peter B. ;
Cohen, David J. .
CIRCULATION, 2008, 118 (06) :632-638
[6]   Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial [J].
Kastrati, A ;
Mehilli, J ;
Neumann, FJ ;
Dotzer, F ;
ten Berg, JN ;
Bollwein, H ;
Graf, I ;
Ibrahim, M ;
Pache, J ;
Seyfarth, M ;
Schühlen, H ;
Dirschinger, J ;
Berger, PB ;
Schömig, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1531-1538
[7]  
Kiyak Julian H., 1996, Polish Journal of Pathology, V47, P27
[8]   Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention [J].
Kizer, JR ;
Muttrej, MR ;
Matthai, WH ;
McConnell, J ;
Nardone, H ;
Sonel, AF ;
Keane, MG ;
Wilensky, RL .
EUROPEAN HEART JOURNAL, 2003, 24 (14) :1314-1322
[9]  
Michaels AD, 2000, AM J CARDIOL, V85, p50B
[10]   Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease [J].
Nageh, T ;
Sherwood, RA ;
Harris, BM ;
Thomas, MR .
HEART, 2005, 91 (09) :1181-1185